The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: A randomized controlled trial

Addiction

Volumn 107, Issue 10, 2012, Pages 1857-1867

  Walker, Natalie ^a   Howe, Colin ^a   Bullen, Chris ^a   Grigg, Michele ^b,c   Glover, Marewa ^a   McRobbie, Hayden ^d   Laugesen, Murray ^e   Parag, Varsha ^a   Whittaker, Robyn ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Quit Group   (New Zealand)

^c Litmus   (New Zealand)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Health NZ Ltd   (New Zealand)

Author keywords

Cessation; Clinical trial; Nicotine replacement therapy; Quest 3; Randomized; Reduced nicotine cigarettes; Smoking

Indexed keywords

NICOTINE; NICOTINE GUM; NICOTINIC AGENT;

ADULT; ARTICLE; BEHAVIOR THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; SMOKING CESSATION; STATISTICS; TOBACCO; TREATMENT OUTCOME;

ADULT; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NICOTINE; NICOTINIC AGONISTS; RECURRENCE; SINGLE-BLIND METHOD; SMOKING CESSATION; TOBACCO PRODUCTS; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866027137     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.03906.x     Document Type: Article

References (42)

1. Rose J. E. Nicotine and non-nicotine factors in cigarette addiction. Psychopharmacology (Berl) 2006; 184: 274-85.
2. Belluzzi J., Wang R., Leslie F. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005; 30: 705-12.
3. Lewis A., Truman P., Hosking M., Miller J. Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type. Tob Control 2012; 21: 39-43.
4. Becker K., Rose J., Albino A. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine Tob Res 2008; 10: 1-10.
5. Rose J., Behm F., Westman E., Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006; 8: 89-101.
6. Rezaishiraz H., Hyland A., Mahoney M. C., O'Connor R. J., Cummings K. M. Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings? Nicotine Tob Res 2007; 9: 1139-46.
7. Hatsukami D. K., Kotlyar M., Hertsgaard L. A., Zhang Y., Carmella S. G., Jensen J. A. etal. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 2010; 105: 343-55.
8. Benowitz N., Dains K., Hall S., Stewart S., Wilson M., Dempsey D. etal. Smoking behaviour and exposure to tobacco toxicants during six months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomark Prev 2012; Epub ahead of print 21 February. DOI: 10.1158/1055-9965 EPI-11-0644.
9. Walker N., Bullen C., McRobbie H. Reduced-nicotine content cigarettes: is there potential to aid smoking cessation? Nicotine Tob Res 2009; 11: 1274-9.
10. Walker N. K., Howe C., Bullen C., Grigg M., Glover M., McRobbie H. etal. Study protocol for a randomised trial of nicotine-free cigarettes as an adjunct to usual NRT-based cessation practice, in people who wish to stop smoking. BMC Public Health 2011; 11: 37-44.
11. Heatherton T., Kozlowski L., Frecker R., Fagerstrom K. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-27.
12. West R., Hajek P. Evaluation of the Mood and Physical Symptoms Scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl) 2004; 177: 195-9.
13. Hughes J. R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007; 9: 315-27.
14. Bush K., Kivlahan D., McDonell M., Fihn S., Bradley K. for the Ambulatory Care Quality Improvement Project (ACQUIP). The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158: 1789-95.
15. West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303.
16. Cappelleri J., Bushmakin A., Baker C., Merikle E., Olufade A. G., Gilbert D. G. Confirmatory factor analysis and reliability of the modified cigarette evaluation questionnaire. Addict Behav 2007; 32: 912-23.
17. Bullen C., Howe C., Lin R. B., Grigg M., Laugesen M., McRobbie H. etal. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction 2010; 105: 1474-83.
18. The Quit Group and the Ministry of Health. Māori Smoking and Tobacco Use 2009. Wellington: Ministry of Health; 2009.
19. Lea R., Benowitz N., Green M., Fowles J., Vishvanath A., Dickson S. etal. Ethnic differences in nicotine metabolic rate among New Zealanders. NZ Med J 2005; 118: U1773.
20. Lea R., Roberst R., Green M., Kennedy M., Chambers G. Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori. NZ Med J 2008; 121: 33-7.
21. Bramley D., Riddell T., Whittaker R., Corbett T., Lin R. B., Wills M. etal. Smoking cessation using mobile phone text messaging is as effective in Maori as non-Maori. NZ Med J 2005; 118: U1494.
22. Holt S., Timu-Parata C., Ryder-Lewis S., Weatherall M., Beasley R. Efficacy of bupropion in the indigenous Maori population of New Zealand. Thorax 2005; 60: 120-3.
23. International Conference on Harmonisation. ICH guideline for clinical safety data management: definitions and standards for expedited reporting. Fed Regist 1995; 60: 11284-7.
24. Li J. How do Quitline callers compare to the New Zealand smoking population? Wellington: The Quit Group; 2007.
25. Ministry of Health. New Zealand Tobacco Use Survey 2006. Wellington: Ministry of Health; 2006.
26. Walker N., Howe C., Bullen C., Grigg M., Glover M., McRobbie H. etal. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction 2011; 106: 1176-85.
27. Society for Research on Nicotine and Tobacco (SRNT) Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4: 149-59.
28. Bullen C., Howe C., Grigg M., Phillips F., Silcock R., Glover M. etal. Recruitment into a cessation trial via the New Zealand Quitline: many benefits, few limitations. J Smoking Cessation 2008; 3: 30-4.
29. Borland R., Segan C. J., Livingston P. M., Owen N. The effectiveness of callback counselling for smoking cessation: a randomized trial. Addiction 2001; 96: 881-9.
30. Elliott H. Post hoc analysis: use and dangers in perspective. J Hypertens Suppl 1996; 14: S21-4.
31. Rothwell P. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176-86.
32. Russell M. Nicotine intake and its regulation by smokers. In: Martin W., Van Loon G., Iwamoto E., Davis L., editors. Tobacco Smoking and Nicotine: A Neurobiological Approach. New York: Plenum Press; 1987, p. 25-50.
33. Rose J. E., Behm F. M., Westman E. C., Johnson M. Dissociating nicotine and non-nicotine components of cigarette smoking. Pharmacol Biochem Behav 2000; 67: 71-81.
34. Brauer L. H., Behm F. M., Lane J. D., Westman E. C., Perkins C., Rose J. E. Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res 2001; 3: 101-9.
35. Buchhalter A. R., Schrinel L., Eissenberg T. Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes. Nicotine Tob Res 2001; 3: 111-8.
36. Butschky M. F., Bailey D., Henningfield J. E., Pickworth W. B. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 1995; 50: 91-6.
37. Perkins K. A., Ciccocioppo M., Conklin C., Milanak M., Grottenhaler A., Sayette M. Mood influences on acute smoking responses are independent of nicotine intake and dose expectancy. J Abnorm Psychol 2008; 117: 79-93.
38. Brody A., Mandelkern M., Costello M., Abrams A., Scheibal D., Farahi J. etal. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol 2009; 12: 305-16.
39. Brody A., Mandelkern M., Olmstead R., Allen-Martinez Z., Scheibal D., Abrams A. etal. Ventral striatal dopamine release in response to smoking a regular versus a denicotinized cigarette. Neuropsychopharmacology 2009; 34: 282-9.
40. Girdhar G., Xu S., Bluestein D., Jesty J. Reduced-nicotine cigarettes increase platelet activation in smokers in vivo: a dilemma in harm reduction. Nicotine Tob Res 2008; 10: 1737-44.
41. Gray N., Henningfield J., Benowitz N., Connolly G., Dresler C., Fagerstrom K. etal. Towards a comprehensive long term nicotine policy. Tob Control 2005; 20: 161-5.
42. Hatsukami D., Perkins K., Lesage M., Ashley D., Henningfield J., Benowitz N. etal. Nicotine reduction revisited: science and future directions. Tob Control 2011; 19: e1-e10.